MBX as reported
- Net Income
- −$104M
Net Income · +35% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$85M
Free Cash Flow · +19% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.36
EPS · −143% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$104M | +35% | Q2 2026 |
| EPS | −$2.36 | −143% | Q2 2026 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −21% | n/a | Q2 2026 |
| Free Cash Flow | −$85M | +19% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
MBX Biosciences, Inc. (MBX) - Net IncomeNet IncomeMBX Biosciences, Inc. (MBX)